Bionoid Pharma : Annual Financial Statements for Year Ending December 31 - 2021 Final

Consolidated Financial Statements of

BIONOID, INC.

December 31, 2021 and 2020

MANAGEMENT'S COMMENTS ON UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTICE OF NO AUDITOR REVIEW OF FINANCIAL STATEMENTS

The accompanying unaudited condensed consolidated financial statements of Bionoid, Inc. (the "Company") have been prepared by and are the responsibility of the Company's management. The unaudited condensed consolidated financial statements are prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS") and reflect management's best estimates and judgment based on information currently available. The Company's independent auditor has not performed a review of these unaudited condensed consolidated financial statements.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF FINANCIAL POSITION (UNAUDITED)

Expressed in U.S. Dollars

December 31, 2021

December 31, 2020

Assets Current assets

Cash and cash equivalents	$ 7,260	$630
Property, plant and equipment	1,473	3,454
Accounts receivable	41,756	-
Patents, trademarks	21,185	24,185
Investment in shares (Note 4)	-	95,466
Total current assets	71,674	123,735
Total assets	$ 71,674	$ 123,735
Liabilities and shareholders' equity
Current liabilities
Loans payable	$ 133,652	$164,637
Accounts payable	9,049	-
Other current liabilities	-	-
Total current liabilities	140,605	164,637
Total liabilities	$142,701	$164,637
Shareholders' equity
Contributed surplus	19,117,093	19,085,761
Shareholders' contribution	9,560	9,560
Accumulated deficit	(20,646,497)	(20,579,745)
Common stock	1,448,817	1,443,522
Total shareholders' equity	(71,027)	(40,902)
Total liabilities and shareholders' equity	71,674	$123,735
On behalf of the Board:
(signed) "Wayne Cockburn"
Director

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

Expressed in U.S. Dollars

Year ended	Year ended
December 31, 2021	December 31, 2020
Revenue
Gross sales	$ 102,120	30,657
Less Cost of sales	(40,296)	(13,585)
Gross profit before operating expenses	61,824	17,072
Operating expenses
Dues and subscriptions	450	-
Office expenses	1,941	251
Professional fees	4,955	6,000
Other expenses	15,610	43,302
22,956	49,453
Gross income (loss)	$ 38,868	$ (32,381)
Other expenses
Loss on sale of shares	$ (60,142)	-
Restatement of value of shares	$ (406,330)
Net income (loss)	$ (21,274)	$ (455,783)

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

BIONOID, INC.

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

Expressed in U.S. Dollars

Capital Stock (Number of Shares)	Capital Stock ($)	Contributed Surplus	Deficit	Total Shareholder's Equity (Deficit)
Balance, December 31, 2020	38,358	$	1,443,522	$	19,085,761	$	(20,579,745)	$	(40,902)
Balance, March 31, 2021	38,358	$	1,443,522	$	19,085,761	$	(20,546,157)	$	473,686
Shares issued for employment agreements	5,440,412	544	9,383
Shares issued for distribution agreement	41,803,126	4,180	72,097
Shares issued upon conversion of debt Balance, September 30, 2021	5,712,714 52,994,610	$	571 1,448,817	$	9,852 19,177,093	$	(20,570,091)	$	780
Shares issued for employment agreements Balance, December 31, 2021	1,000,000 53,994,610	$	100 1,448,917	$	1,725 19,178,818	$	(20,646,497)	$	780

The accompanying notes are an integral part of these condensed consolidated interim financial statements.